The company has informed NICE that it will not provide an evidence submission for this appraisal. Therefore, we are suspending the appraisal while we consider the next steps
 
Status Suspended
Decision Selected
Process STA 2018

Timeline

Key events during the development of the guidance:

Date Update
06 October 2020 The Department for Health and Social Care has asked NICE to conduct an appraisal of enasidenib for treating IDH2-positive acute myeloid leukaemia after 2 or more therapies. However, the company have advised that the European Medicines Agency Committee for Medicinal Products (CHMP) have issued a negative opinion for enasidenib for treating IDH2-positive acute myeloid leukaemia after 2 or more therapies. Therefore, NICE has decided to suspend this appraisal from its work program. As this appraisal has been referred to NICE we will continue to monitor any development and will update interested parties if the situation changes.
01 February 2019 Suspended. The company has informed NICE that it will not provide an evidence submission for this appraisal. Therefore, we are suspending the appraisal while we consider the next steps
31 July 2017 In progress. Topic referred
13 July 2017 Referral

For further information on our processes and methods, please see our CHTE processes and methods manual